ClinicalTrials.gg
Active, not recruitingNCT04606771CoCUpdated Jul 30, 2026Results posted

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

A Phase 2 interventional study of Osimertinib + Savolitinib and Savolitinib + Placebo in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
64th of 90
30 · median 51
Started
2020
with 7 others
Phase 2
46 of 90
12 open now
Primary completion
2022-12
later than 3 of 42 live
Registered
55th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 64th largest by enrollment, is one of 8 that started in 2020, is one of 46 in phase 2, reaches primary completion later than 3 of the 42 other live ones, and was the 55th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.

Read the detailed description

Resistance to EGFR-TKIs is a clinical problem. One of the mechanisms for resistance to osimertinib is amplification of the MET receptor tyrosine kinase, which activates downstream intracellular signalling independent of EGFR. This study will explore the individual contribution of savolitinib to MET mediated osimertinib resistance, by assessing the response to dual pathway blockade of EGFRm and MET to overcome MET mediated resistance to osimertinib versus inhibition of the MET pathway alone by investigating the efficacy of savolitinib plus osimertinib versus savolitinib plus placebo to osimertinib (hereafter referred to as placebo) in patients with EGFRm+ and MET amplified, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib. This is a multi centre, Phase II, double blind, randomised study.

Patients will be randomised in a ratio of 1:1 to receive treatment with savolitinib once daily plus osimertinib once daily or savolitinib once daily plus placebo. Randomisation will be stratified according to the number ofprior lines of therapy (ie, osimertinib monotherapy as first line or ≥ second line [which includes patients who received osimertinib monotherapy before or after chemotherapy]). All patients confirmed as eligible will begin treatment on Day 1 with savolitinib plus osimertinib or savolitinib plus placebo. Treatment will continue once daily in 28 day cycles until either objective PD by RECIST 1.1 is assessed, unacceptable toxicity occurs, consent is withdrawn, or another discontinuation criterion is met.

After progression, patients can be unblinded, and patients initially randomised to the savolitinib plus placebo arm may cross-over to open-label savolitinib plus osimertinib following investigator assessed objective PD to ensure that all patients enrolled may have the opportunity to receive the combination of savolitinib plus osimertinib.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Locally
  • Advanced
  • Metastatic
  • Carcinoma
  • Non-Small Cell Lung Cancer
  • Osimertinib
  • Tagrisso
  • Savolitinib
  • MET
  • EGFR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years of age at the time of signing the (≥ 20 years of age in Japan). All genders are permitted
  • or cytologically confirmed locally advanced or EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and that is permitted in the osimertinib national label (such as exon 19 deletion and/or L858R), which is not amenable to curative therapy.
  • Documented radiologic PD following treatment with osimertinib (osimertinib does not need to be the most recent therapy).
  • Have MET amplification as determined by central MET FISH testing on tumour specimen collected following progression on prior osimertinib treatment.
  • At least measurable target lesion
  • Patients must have received at least one but no more than 3 (including therapy) in the locally advanced/metastatic setting.
  • Adequate haematological, liver and renal function
  • /WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  • Females of should be willing to use adequate measures, should not be breastfeeding, and must have a negative pregnancy test.
  • Male patients with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 6 months following discontinuation of study intervention. Patients should refrain from donating sperm from the start of dosing until 6 months after discontinuing study intervention.

Exclusion criteria

Exclusion Criteria:

  • Unresolved toxicities from any prior therapy greater than Grade 1 at the time of starting study intervention with the exception of alopecia, ≥ 9 g/dL and Grade 2, prior platinum therapy related neuropathy.
  • As judged by the investigator, active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy.
  • Any of the following cardiac diseases currently or within the last 6 months:

    • Unstable angina pectoris
    • Congestive heart failure ( Grade ≥ 2)
    • Acute myocardial infarction
    • Stroke or
    • Uncontrolled hypertension (BP ≥ 150/95 mmHg despite medical therapy).
    • Mean resting interval (QTcF) > 470 msec for women and > 450 msec for men at Screening, obtained from 3 ECGs using the screening clinic machine derived QTcF value.
    • Any factors that may increase the risk of QTcF prolongation or risk of arrhythmic events
    • Any abnormalities in rhythm, conduction or morphology of resting ECGs.
    • Acute coronary syndrome
  • Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤ 28 days or limited field radiation for palliation ≤ 7 days prior to starting study intervention or has not recovered from side effects of such therapy.
  • Major surgical procedures ≤ 28 days of beginning study intervention or minor surgical procedures ≤ 7 days. No waiting is required following port-a-cath placement.
  • As judged by the Investigator, any evidence of severe or uncontrolled systemic diseases, including renal transplant or active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to enter the study or which would jeopardise compliance with the CSP.
  • Active (positive HBsAg result) or . Viral testing is not required for assessment of eligibility for the study.
  • Known serious active infection including, but not limited to, tuberculosis, or (positive HIV 1/2 antibodies). Testing is not required for assessment of eligibility for the study.
  • Presence of other active cancers, or history of treatment for invasive cancer, within the last 5 years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
  • Spinal cord compression or unless asymptomatic, stable and not requiring for at least 2 weeks prior to start of study intervention.
  • Past medical history of ILD, drug-induced ILD, radiation pneumonitis, which required steroid treatment, or any evidence of clinically active ILD.
  • Prior or current treatment with a 3rd generation EGFR-TKI other than osimertinib.
  • Prior or current treatment with savolitinib or another MET inhibitor (for example, foretinib, crizotinib, cabozantinib, onartuzumab, capmatinib).
  • Patients who have received ≥ 4 for NSCLC
  • Any cytotoxic chemotherapy, agents or other anti cancer drugs for the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days prior to the first dose of study intervention with the exception of monotherapy osimertinib which may continue uninterrupted during screening.
  • Patients currently receiving (or unable to stop use prior to receiving the first dose of study intervention) medications or herbal supplements known to be strong inducers of or strong inhibitors of CYP1A2, or CYP3A4 substrates which have a narrow therapeutic range within 2 weeks of the first dose of study intervention (3 weeks for St John's Wort) will be excluded. All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer effects on CYP3A4 during the study and for 3 months later the last dose intake.
  • Participation in another clinical study with a cytotoxic, investigational product, or other anti cancer drug for the treatment of advanced NSCLC if received study intervention from that study within 14 days of the first dose of study intervention.
  • Known to the active or inactive of osimertinib or savolitinib or drugs with a similar chemical structure or class.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Arm A

    Savolitinib 300 mg oral QD Osimertinib 80 mg oral QD

    Drug: Osimertinib + Savolitinib

  • Experimental
    Arm B

    Savolitinib 300 mg oral QD Placebo to Osimertinib 80mg oral QD

    Drug: Savolitinib + Placebo

Interventions

  • DrugOsimertinib + Savolitinib

    Drug pages: Osimertinib · Savolitinib

    Osimertinib 80 mg oral QD Savolitinib 300mg oral QD

  • DrugSavolitinib + Placebo

    Savolitinib 300mg Oral QD Placebo to Osimertinib 80mg oral QD

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesions. Overall Response (OR) = CR + PR.

    Time frame: Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Progression (i.e., PD) is defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters.

    Time frame: Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)

  2. Duration of Response (DoR)

    DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator or death in the absence of disease progression.

    Time frame: Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)

  3. Tumour Size Assessment (TSA)

    TSA is defined as the percentage change from baseline in TLs at 12 weeks per RECIST 1.1 as assessed by the investigator.

    Time frame: Baseline and 12 weeks.

  4. Overall Survival (OS)

    OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: From the date of randomisation until death due to any cause, assessed up to the data cut-off date (21 December 2022) (maximum of approximately 25 months)

  5. Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Percentage Change From Baseline in EGFR Mutation Allele Frequencies).

    To determine the prevalence of ctDNA clearance after savolitinib plus osimertinib or savolitinib plus placebo treatment in this patient population

    Time frame: 6-weeks after therapy initiation.

  6. Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Absolute Change From Baseline in EGFR Mutation Allele Frequencies).

    To determine the prevalence of ctDNA clearance after savolitinib plus osimertinib or savolitinib plus placebo treatment in this patient population

    Time frame: 6-weeks after therapy initiation.

  7. PK Concentration Ratios on Multiple Dosing

    The time dependency of the PK on multiple dosing is assessed by the ratio of mean concentrations at the timepoints identified in column one. For example, the Geometric mean ratio for "C3h Cycle2 Day 1 / C3h Cycle 1 Day 1" periods is the geometric mean value for C3h Cycle 2 Day 1 (Stage 2) divided by the geometric mean value for C3h Cycle 1 Day 1 (Stage 1). Because the measurement is a ratio of values, no measures of central tendency are appropriate.

    Time frame: C3h Cycle 2 Day 1/C3h Cycle 1 Day 1; Cpre-dose Cycle 3 Day 1/Cpre-dose Cycle 2 Day 1; Cpre-dose Cycle 6 Day 1/Cpre-dose Cycle 2 Day 1; Cpre-dose Cycle 11 Day 1/Cpre-dose Cycle 2 Day 1. (Each Cycle is 28 days)

  8. AUCss of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

    Area under the plasma concentration-time curve at steady state

    Time frame: Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose

  9. Cssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

    Maximum steady state plasma concentration

    Time frame: Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose

  10. Tssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

    Time to maximum plasma concentration at steady state

    Time frame: Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose

  11. CLss/F of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

    To evaluate the PK of savolitinib and osimertinib.

    Time frame: Cycle 3, Day 1 (Each Cycle is 28 days)

07

Results

Posted Sep 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Started1416
Completed00
Not completed1416
Withdrew: Patients ongoing study at data cut-off99
Withdrew: Death56
Withdrew: Wrong randomisation01

Outcome measures

PrimaryObjective Response Rate (ORR)

Percentage of evaluable patients with an Investigator-assessed visit response of complete response (CR) or partial response (PR). CR defined as disappearance of all target and non-target lesions and no new lesions. PR defined as \>= 30% decrease in the sum of diameters of target lesions (compared to baseline) and no new non-target lesions. Overall Response (OR) = CR + PR.

Time frame:
Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Objective Response Rate (ORR)57.1 (28.86 to 82.34)12.5 (1.55 to 38.35)
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression. Progression (i.e., PD) is defined as at least a 20% increase in the sum of diameters of target lesions (TLs) and an absolute increase of ≥5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters.

Time frame:
Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Progression-free Survival (PFS)7.36 (5.55 to NA)1.64 (1.28 to 4.07)
SecondaryDuration of Response (DoR)

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1 as assessed by the investigator or death in the absence of disease progression.

Time frame:
Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months)
Reported as:
Median · Weeks
Duration of Response (DoR)
WeeksSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Duration of Response (DoR)30.57 (18.86 to NA)NA (12.43 to NA)
SecondaryTumour Size Assessment (TSA)

TSA is defined as the percentage change from baseline in TLs at 12 weeks per RECIST 1.1 as assessed by the investigator.

Time frame:
Baseline and 12 weeks.
Reported as:
Mean · Percentage change
Tumour Size Assessment (TSA)
Percentage changeSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Tumour Size Assessment (TSA)-35.0 ± 29.628.5 ± 38.95
SecondaryOverall Survival (OS)

OS is defined as time from randomisation until the date of death due to any cause.

Time frame:
From the date of randomisation until death due to any cause, assessed up to the data cut-off date (21 December 2022) (maximum of approximately 25 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Overall Survival (OS)NA (9.56 to NA)13.37 (7.82 to NA)
SecondaryTotal Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Percentage Change From Baseline in EGFR Mutation Allele Frequencies).

To determine the prevalence of ctDNA clearance after savolitinib plus osimertinib or savolitinib plus placebo treatment in this patient population

Time frame:
6-weeks after therapy initiation.
Reported as:
Mean · Allele Frequency
Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Percentage Change From Baseline in EGFR Mutation Allele Frequencies).
Allele FrequencySavolitinib Plus OsimertinibSavolitinib Plus Placebo
Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Percentage Change From Baseline in EGFR Mutation Allele Frequencies).-93.6 ± 11.03-62.7 ± 48.73
SecondaryTotal Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Absolute Change From Baseline in EGFR Mutation Allele Frequencies).

To determine the prevalence of ctDNA clearance after savolitinib plus osimertinib or savolitinib plus placebo treatment in this patient population

Time frame:
6-weeks after therapy initiation.
Reported as:
Mean · Allele Frequency
Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Absolute Change From Baseline in EGFR Mutation Allele Frequencies).
Allele FrequencySavolitinib Plus OsimertinibSavolitinib Plus Placebo
Total Clearance in EGFR Mutations at 6-weeks After Therapy Initiation (Absolute Change From Baseline in EGFR Mutation Allele Frequencies).-17.4 ± 17.59-2.9 ± 2.93
SecondaryPK Concentration Ratios on Multiple Dosing

The time dependency of the PK on multiple dosing is assessed by the ratio of mean concentrations at the timepoints identified in column one. For example, the Geometric mean ratio for "C3h Cycle2 Day 1 / C3h Cycle 1 Day 1" periods is the geometric mean value for C3h Cycle 2 Day 1 (Stage 2) divided by the geometric mean value for C3h Cycle 1 Day 1 (Stage 1). Because the measurement is a ratio of values, no measures of central tendency are appropriate.

Time frame:
C3h Cycle 2 Day 1/C3h Cycle 1 Day 1; Cpre-dose Cycle 3 Day 1/Cpre-dose Cycle 2 Day 1; Cpre-dose Cycle 6 Day 1/Cpre-dose Cycle 2 Day 1; Cpre-dose Cycle 11 Day 1/Cpre-dose Cycle 2 Day 1. (Each Cycle is 28 days)
Reported as:
Number · Geometric mean ratio
PK Concentration Ratios on Multiple Dosing
Geometric mean ratioSavolitinibOsimertinib
C3h Cycle 2 Day 1 / C3h Cycle 1 Day 10.88121.081
Cpre-dose Cycle 3 Day 1 / Cpre-dose Cycle 2 Day 10.86501.032
Cpre-dose Cycle 6 Day 1 / Cpre-dose Cycle 2 Day 10.63521.068
SecondaryAUCss of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

Area under the plasma concentration-time curve at steady state

Time frame:
Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose
Reported as:
Geometric mean · h*ng/mL
AUCss of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)
h*ng/mLSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Savolitinib7875 ± 37.5411890 ± 37.56
M22630 ± 48.803516 ± 44.43
M3966.7 ± 49.071348 ± 42.37
Osimertinib12910 ± 50.80—
AZ51041086 ± 70.80—
SecondaryCssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

Maximum steady state plasma concentration

Time frame:
Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose
Reported as:
Geometric mean · ng/mL
Cssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)
ng/mLSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Savolitinib1282 ± 35.652058 ± 32.00
M2351.0 ± 39.91581.5 ± 21.19
M3129.0 ± 34.90213.9 ± 36.08
Osimertinib678.3 ± 50.80—
AZ510451.23 ± 70.14—
SecondaryTssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

Time to maximum plasma concentration at steady state

Time frame:
Cycle 3, Day 1: Pre-dose and 1, 3, 4, and 6 hours post-dose
Reported as:
Median · h
Tssmax of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)
hSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Savolitinib3.00 (1.00 to 5.62)3.00 (0.95 to 6.00)
M23.00 (1.00 to 5.62)1.05 (0.95 to 6.00)
M33.00 (0.92 to 5.78)1.05 (0.95 to 6.00)
Osimertinib4.00 (3.00 to 6.00)—
AZ51044.00 (0.00 to 6.00)—
SecondaryCLss/F of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)

To evaluate the PK of savolitinib and osimertinib.

Time frame:
Cycle 3, Day 1 (Each Cycle is 28 days)
Reported as:
Geometric mean · L/h
CLss/F of Savolitinib, Osimertinib and Their Metabolites, (M2 and M3 for Savolitinib; AZ5104 for Osimertinib)
L/hSavolitinib Plus OsimertinibSavolitinib Plus Placebo
Savolitinib38.10 ± 37.5425.23 ± 37.56
M2114.1 ± 48.8085.32 ± 44.43
M3310.3 ± 49.07222.5 ± 42.37
Osimertinib0.01241 ± 50.80—
AZ51040.1475 ± 70.80—

Adverse events

Collected over Collected throughout the study, from date of informed consent until 28 days after the last dose of study treatment (or end of follow up period). All-cause mortality (death due to any cause): from randomisation up to data cut-off date (21 Dec 2022). Maximum timeframe of approximately 24.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Savolitinib Plus Osimertinib5/14 (35.7%)4/14 (28.6%)13/14 (92.9%)
Savolitinib Plus Placebo7/16 (43.8%)3/16 (18.8%)16/16 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSavolitinib Plus OsimertinibSavolitinib Plus Placebo
PneumoniaInfections and infestations0/143/16
PyrexiaGeneral disorders1/140/16
SepsisInfections and infestations1/140/16
Wound necrosisInjury, poisoning and procedural complications1/140/16
Hepatic enzyme increasedInvestigations1/140/16
Diabetes mellitusMetabolism and nutrition disorders1/140/16
HypernatraemiaMetabolism and nutrition disorders1/140/16
HaematuriaRenal and urinary disorders1/140/16
Deep vein thrombosisVascular disorders1/140/16
HypertensionVascular disorders1/140/16
Most frequent other events
Showing 10 of 68
Most frequent other events
EventSavolitinib Plus OsimertinibSavolitinib Plus Placebo
NauseaGastrointestinal disorders7/143/16
Oedema peripheralGeneral disorders5/144/16
VomitingGastrointestinal disorders3/145/16
HeadacheNervous system disorders4/140/16
Amylase increasedInvestigations2/144/16
Decreased appetiteMetabolism and nutrition disorders1/144/16
FatigueGeneral disorders3/140/16
HypoalbuminaemiaMetabolism and nutrition disorders3/142/16
Dermatitis acneiformSkin and subcutaneous tissue disorders3/140/16
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/143/16

Baseline characteristics

Full analysis set

Age, Continuous
Age, Continuous(Years)Savolitinib Plus OsimertinibSavolitinib Plus PlaceboTotal
Mean56.2 ± 11.4262.5 ± 10.0259.6 ± 10.98
Sex: Female, Male
Sex: Female, Male(Participants)Savolitinib Plus OsimertinibSavolitinib Plus PlaceboTotal
Female7916
Male7714
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Savolitinib Plus OsimertinibSavolitinib Plus PlaceboTotal
Asian121527
White101
Other011
Not reported101
08

Study locations

21 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Ciudad de Buenos Aires, C1120AAT, Argentina
  • Research Site
    Delhi, 110085, India
  • Research Site
    Mumbai, 400053, India
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Taoyuan City, 333, Taiwan
  • Research Site
    Bangkok, 10210, Thailand
  • Research Site
    Bangkok, 10300, Thailand
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Muang, 50200, Thailand
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Hà Nội, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2022, 26 months.

Results were first posted in Sep 2024, 1 year 9 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 26 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2020
First posted
Oct 28, 2020
StartActual
Sep 28, 2020
Primary completionActual
Dec 21, 2022
CompletionEst.
Mar 15, 2027
Results first posted
Sep 24, 2024
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04606771
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 28, 2020
Start date
Sep 28, 2020
Primary completion
Dec 21, 2022
Completion
Mar 15, 2027 (estimated)
Results posted
Sep 24, 2024
Last update
Jul 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Osimertinib · Savolitinib

Start the discussion